Repositori URV

Identificador: TDX:496

Handle: https://hdl.handle.net/20.500.11797/TDX496

Autores:
Pelegrí Sarlé, Amadeo

Resumen:
We sought to evaluate outcomes and the most likely prognostic factors associated with the use of sequential doxorubicin + cyclophosphamide-methotrexate-fluorouracil administered prior to scheduled radiation therapy, in non-selected consecutive patients (n=163) with 4 positive nodes. Variables included in statistical analyses included age, menopausal status, tumour size, histology grade, number of positive nodes (4 to 9 or 10), oestrogen and progesterone receptors (ER, PR), HER-2 status and chemotherapy-induced amenorrhoea. With a median follow-up of 86 months, the results showed disease-free survival (DFS) at 5 years was 68% and overall survival (OS) was 78% and no toxic deaths. Number of positive nodes, tumour size, histology grade and amenorrhoea showed prognostic significance for DFS and OS. ER and PR reached significance only for OS. HER-2 positive status did not predict poorer DFS or OS. Tumor size > 2 cm, 10+ positive nodes and grade 3 tumours predicted DFS and OS in multivariate analysis. Amenorrhoea reach prognostic significance for DFS and OS in premenopausal patients. We conclude that DOXCMF is an effective and safe regimen. Number of positive axillary nodes, histologic grade and tumor size , but not HER2 status, are predictive of outcome. Amenorrhoea favour DFS and OS in premenopausal patients.